复宏汉霖(02696):给予"买入"评级,上调目标价至104.79港元 美国高盛 高盛发布研报称，给予复宏汉霖(65.65,1.50,2.34%)(02696)为"买入"评级，将公司今年及明年销售预 测分别上调8.6%及8.3%，维持2028年销售预测不变，而各年纯利预测则分别上调3,800万元人民币、2.24亿元 人民币及1.43亿元人民币，其目标价由102.72港元上调至104.79港元。 该行指出，复宏汉霖去年下半年总收入同比升29%至38亿元人民币，其中中国内地销售胜于预期，同比升 31%至32亿元人民币。至于海外收入全年达2.58亿元人民币，其中HLX02贡献约1.8亿元人民币，海外利润主要 来自HLX02在美国的销售。下半年盈利超出预期，受惠于收入增长强劲和毛利率不断提升。 ...

23 March 2026 | 8:28AM HKT Equity Research Henlius Biotech (2696.HK): Earnings Review: Solid topline with sustainable profitability; Overseas biosimilar near inflection; Buy Solid 2H driven by PD-1 and diversifying portfolio: 2H total revenue was Rmb3.8bn (+29% y/y) with China sales better than our expectations (Rmb3.2bn, +31% y/y vs GSe Rmb2.7bn). Key drivers include: 1) serplulimab (+34% y/y) with deeper penetration among small-cell lung cancer patients and new hospital expansion; 2) China biosimilar port ...